Bioanalytical testing company Eurofins Scientific has agreed to pay $140 million to buy fast-growing Boston Heart Diagnostics Corp. of Framingham, a portfolio company of Bain Capital Ventures, the companies said Monday.
Eurfins, based in Luxembourg, will operate Boston Heart as a wholly owned subsidiary and retain all of its 350 employees, a company statement said. Boston Heart, which projects revenues of about $95 million this year, develops and markets tests to identify and reduce the risk of cardiovascular disease, diabetes, and other chronic conditions.
Boston Heart said in September that it was responding to inquiries from US investigators examining whether diagnostic firms improperly paid doctors who send them patients’ blood specimens to test their risk for cardivascular disease. The Framingham company said it was “fully cooperating” with the probe by the Department of Justice and the inspector general’s office of the Department of Health and Human Services.